Publications by authors named "E Turba"
Article Synopsis
- Advancements in CLL/SLL treatments have led to a study exploring a new frontline therapy combining high-dose methylprednisolone, ofatumumab, and lenalidomide for treatment-naive patients.
- In a phase 2 study involving 45 patients, the treatment showed a 96% overall response rate and a median progression-free survival of 54.4 months, with 29% achieving a complete response.
- Although the treatment was generally well tolerated, with manageable side effects, the effectiveness compared to existing treatments remains uncertain, highlighting the need for further research in the frontline setting.
ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin (BV) is approved with AVD for stage III-IV HL, but carries increased risks of peripheral neuropathy (PN) and neutropenic fever, likely due to overlapping toxicity between BV and vinblastine. We therefore evaluated BV in combination with AD for 4 or 6 cycles based on interim positron emission tomography response.
View Article and Find Full Text PDFBackground: Clinical Research Nurses practice across a wide spectrum of roles and settings within the global research enterprise. Clinical Research Nurses working with clinical trials face a dual fidelity in their role, balancing integrity of the protocol and quality care for participants.
Aims: The purpose of this study was to describe Clinical Research Nurses' experiences in clinical trials, educational preparation, and career pathways, to gain a deeper understanding of clinical research nursing contributions to the clinical research enterprise.
Chronic lymphocytic leukemia (CLL) is an incurable disease in need of new therapeutic strategies. The immunomodulatory agent, lenalidomide, has shown activity as salvage therapy for CLL. In this phase II trial, we combined lenalidomide with rituximab in 25 patients (range, 41-79) with refractory/relapsed CLL.
View Article and Find Full Text PDF